RxDoctor Payments Data

Florence Arnold, MD

Hematology & Oncology · Watertown, NYNPI 1225424369

Payments from drug & device makers

$12,296in general payments, 2019–2025

Across 562 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Johnson & Johnson$1K
  • Merck$908
  • Novartis$785
  • Pfizer$508
  • Bristol Myers Squibb$488
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$12,10798%
  • Education$1892%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca52$1,512
Johnson & Johnson(2 entities)35$1,018
Merck53$908
Novartis50$785
Pfizer35$508
Bristol Myers Squibb30$488
Lilly USA, LLC16$480
E.r. Squibb & Sons, L.L.C.21$447
Sanofi17$418
AbbVie19$406
Incyte Corporation13$377
Daiichi Sankyo Inc.24$360
Eisai Inc.11$348
Amgen11$344
Regeneron Healthcare Solutions, Inc.8$283
Takeda Pharmaceuticals U.S.A., Inc.12$278
Sobi, Inc3$263
Genentech USA, Inc.14$250
Bayer11$216
Puma Biotechnology, Inc.12$205
EMD Serono, Inc.9$174
GSK7$161
Karyopharm Therapeutics Inc.7$152
Genmab U.S., Inc.2$141
Astellas Pharma US Inc7$123
Epizyme, Inc.1$113
Exelixis Inc.7$110
Jazz Pharmaceuticals Inc.5$101
Novocure Inc.2$99
Tersera Therapeutics LLC5$98
Foundation Medicine, Inc.2$85
Seagen Inc.5$82
Myriad Genetic Laboratories, Inc.4$73
Ipsen Biopharmaceuticals, Inc3$70
Partner Therapeutics, Inc.4$68
Verastem, Inc.4$57
Boston Scientific2$54
Tempus AI, Inc1$47
Gilead3$44
Array Biopharma Inc2$43
Fortovia Therapeutics, Inc.3$40
Clovis Oncology, Inc.3$36
Boehringer Ingelheim2$34
AMAG Pharmaceuticals, Inc.2$31
Beigene USA, Inc.2$30
Agios Pharmaceuticals, Inc.2$29
Servier Pharmaceuticals LLC2$28
Blueprint Medicines Corporation1$20
Shire North American Group Inc1$20
West Therapeutics Development, LLC1$18
Springworks Therapeutics, Inc.1$18
Telix Pharmaceuticals1$18
Myovant Sciences Inc.1$18
Taiho Oncology, Inc.1$18
Adaptive Biotechnologies Corporation1$17
Pharmacyclics LLC, An Abbvie Company1$17
Sumitomo Pharma America, Inc.1$17
AVEO Pharmaceuticals, Inc.1$16
Beone Medicines USA, Inc.1$15
Advanced Accelerator Applications1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,296 in reported general payments places this provider in the 60th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York

Medicare billing

Part B allowed, 2024
$63,297
Medicare patients
346
Services billed
808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate25$523,636
XtandiEnzalutamide29$418,727
IbrancePalbociclib19$396,205
Lenalidomide17$255,953
VerzenioAbemaciclib18$252,480
BrukinsaZanubrutinib14$187,077
ImbruvicaIbrutinib12$184,333
NinlaroIxazomib Citrate13$163,537
CalquenceAcalabrutinib Maleate12$92,393
Abiraterone Acetate18$52,126
Imatinib Mesylate23$35,601
EliquisApixaban28$17,931
XareltoRivaroxaban23$12,465
Exemestane38$6,053
Letrozole202$3,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$377$523,63625 claims
Astellas Pharma US IncXtandi$123$418,72729 claims
PfizerIbrance, Eliquis$508$414,13747 claims
Lilly USA, LLCVerzenio$480$252,48018 claims
Beigene USA, Inc.Brukinsa$30$187,07714 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$17$184,33312 claims
Takeda Pharmaceuticals U.S.A., Inc.Ninlaro$278$163,53713 claims
AstraZenecaCalquence$1,512$92,39312 claims
Johnson & JohnsonXarelto$1,018$12,46523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 967 hematology & oncology providers in New York.

Other hematology & oncology in Watertown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →